Irbesartan Tablet
Product Images NDC 70518-2685

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Irbesartan (NDC 70518-2685). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Irbesartan 75mg 70518 2685 00

Irbesartan 75 mg tablet label from RemedyRepack Inc. The label shows the product name, strength (75 mg), dosage form (tablet), and quantity (90). It includes NDC number 70518-2685-00 and repackaging information by RemedyRepack, Indiana, PA. Manufacturer is Camber Pharma, Piscataway, NJ. Directions advise referring to the package insert and storage instructions are present.*

FDA Label Image

Irbesartan 75mg 70518 2685 01

Irbesartan 75 mg oral tablet packaging label showing a quantity of 90 tablets. The label includes the NDC number 70518-2685-01 and specifies repackaging by RemedyRepack Inc. It also mentions the original manufacturer as Camber Pharma, Inc. Storage temperature instructions and a QR code are visible, alongside a note to keep the medication out of reach of children.*

FDA Label Image

Irbesartanfigure3.jpg (Irbesartanfigure3)

A line graph showing cumulative event rates (%) over 60 months of follow-up for three groups: Irbesartan, Amlodipine, and Placebo. The graph compares the event rates of Irbesartan versus Placebo and Amlodipine, including p-values and relative risk (RR) values in a legend box.*

FDA Label Image

Image1 (Image1)

Chemical structure of Irbesartan, showing its molecular framework with characteristic ring systems and functional groups typical for this angiotensin II receptor antagonist drug.*

FDA Label Image

Image2 (Image2)

Two scatter plots with trend lines showing the placebo-subtracted reduction in trough SeSBP and SeDBP versus Irbesartan dose (mg/day). Figure 1 shows systolic blood pressure reduction, and Figure 2 shows diastolic blood pressure reduction, both plotted against increasing Irbesartan doses up to about 900 mg/day.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.